Literature DB >> 8633254

Relevant parameters for describing the oxygenation status of solid tumors.

O Thews1, P Vaupel.   

Abstract

AIM: Several studies using different methods of pO2 measurement have shown that in many tumor entities tissue oxygenation is quite heterogeneous and thus cannot be sufficiently described by a single value. This study presents those distribution parameters which are mandatory to describe the complete oxygenation status of a solid tumor.
METHODS: In determining the oxygenation status different aspects of relevancy have to be taken into account. First, several parameters are necessary to characterize the location, the spread, and the shape of the pO2 distribution from a statistical point of view (statistical parameters). In addition, parameters for the description of the biological relevance of the tumor oxygenation have to be considered (biological parameters). These parameters reflect the role of oxygenation for the metabolic microenvironment and the biological behavior of the tumor as well as the significance under therapeutic and diagnostic aspects. Finally, some parameters are necessary to assess the quality of pO2 measurement itself (quality parameters).
RESULTS: By combining all pO2 readings from one tumor a statistical distribution is obtained, which is in many tumors asymmetrically shifted towards low pO2 values. In order to describe the location, spread, and shape of this distribution the following parameters should be stated: median, mean, 10% and 90% percentile, minimum, maximum and 10 to 90% interpercentile range. For data presentation these values can be combined in a box-whiskers plot. In order to reflect the importance of tumor oxygenation under diagnostic, therapeutic or cell-biological aspects the fraction of pO2 readings < or = 2.5 mm Hg, < or = 5 mm Hg, and < or = 10 mm Hg should be stated. Where negative pO2 readings occur in a study, the fraction of pO2 readings < 0 mm Hg as well as the most negative pO2 value should be presented in order to assess the quality of the pO2 measurement.
CONCLUSIONS: For a comprehensive description of the oxygenation status of solid tumors the following distribution parameters should be stated: median, mean, 10% and 90% percentile, minimum, maximum, 10 to 90% interpercentile range, fraction of pO2 readings < 0 mm Hg, < or = 2.5 mm Hg, < or = 5 mm Hg, and < or = 10 mm Hg as well as the most negative pO2 reading.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8633254

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  5 in total

1.  Spatial oxygenation profiles in tumors during normo- and hyperbaric hyperoxia.

Authors:  Oliver Thews; Peter Vaupel
Journal:  Strahlenther Onkol       Date:  2015-07-02       Impact factor: 3.621

2.  [Intratumor pO2, S-phase fraction and p53 status in cervix carcinomas].

Authors:  G Hänsgen; I Hintner; V Krause; W Wohlrab; J Dunst
Journal:  Strahlenther Onkol       Date:  1997-07       Impact factor: 3.621

Review 3.  Measurements in vivo of parameters pertinent to ROS/RNS using EPR spectroscopy.

Authors:  Nadeem Khan; Harold Swartz
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

4.  A 2-week pretreatment with 13-cis-retinoic acid + interferon-alpha-2a prior to definitive radiation improves tumor tissue oxygenation in cervical cancers.

Authors:  J Dunst; G Hänsgen; U Krause; G Füchsel; U Köhler; A Becker
Journal:  Strahlenther Onkol       Date:  1998-11       Impact factor: 3.621

5.  pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia?

Authors:  Bernd Gagel; Marc Piroth; Michael Pinkawa; Patrick Reinartz; Michael Zimny; Hans J Kaiser; Sven Stanzel; Branka Asadpour; Cengiz Demirel; Kurt Hamacher; Heinz H Coenen; Thomas Scholbach; Payam Maneschi; Ercole DiMartino; Michael J Eble
Journal:  BMC Cancer       Date:  2007-06-28       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.